{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T21:06:45Z","timestamp":1790197605317,"version":"4.1.0"},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T00:00:00Z","timestamp":1790121600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003704","name":"Korea Research Institute of Chemical Technology","doi-asserted-by":"publisher","award":["KK2631-10"],"award-info":[{"award-number":["KK2631-10"]}],"id":[{"id":"10.13039\/501100003704","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Peptides"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.peptides.2026.171517","type":"journal-article","created":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T06:39:39Z","timestamp":1789627179000},"page":"171517","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["KR-36996, an orally active urotensin II receptor antagonist, attenuates hepatic inflammation and fibrosis in methionine- and choline-deficient diet-induced fibrosing steatohepatitis"],"prefix":"10.1016","volume":"201","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-2918-1944","authenticated-orcid":false,"given":"Ye Sol","family":"Han","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0849-0086","authenticated-orcid":false,"given":"Seung Hyeong","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-0976-6143","authenticated-orcid":false,"given":"Seo Young","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3118-9072","authenticated-orcid":false,"given":"Kyeong Eun","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4242-0818","authenticated-orcid":false,"given":"Kwang-Seok","family":"Oh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Byung Ho","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0504-0119","authenticated-orcid":false,"given":"Jeong Hyun","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.peptides.2026.171517_bib1","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/j.tem.2024.02.007","article-title":"Current status and future trends of the global burden of MASLD","volume":"35","author":"Miao","year":"2024","journal-title":"Trends Endocrinol. Metab."},{"issue":"4","key":"10.1016\/j.peptides.2026.171517_bib2","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1097\/HEP.0000000000000004","article-title":"The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review","volume":"77","author":"Younossi","year":"2023","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.peptides.2026.171517_bib3","doi-asserted-by":"crossref","DOI":"10.1002\/edm2.70132","article-title":"Metabolic dysfunction-associated steatotic liver disease (MASLD): mechanisms, clinical implications and therapeutic advances","volume":"8","author":"Miller","year":"2025","journal-title":"Endocrinol. Diabetes Metab."},{"issue":"4","key":"10.1016\/j.peptides.2026.171517_bib4","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.3390\/ijms26041778","article-title":"Current therapeutic landscape for metabolic dysfunction-associated steatohepatitis","volume":"26","author":"Devasia","year":"2025","journal-title":"Int. J. Mol. Sci."},{"issue":"9","key":"10.1016\/j.peptides.2026.171517_bib5","first-page":"S159","article-title":"Management strategies for metabolic dysfunction-associated steatotic liver disease (MASLD)","volume":"30","author":"Alkhouri","year":"2024","journal-title":"Am. J. Manag. Care"},{"issue":"5","key":"10.1016\/j.peptides.2026.171517_bib6","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1002\/hep.29085","article-title":"Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: systematic review and meta-analysis","volume":"65","author":"Dulai","year":"2017","journal-title":"Hepatology"},{"issue":"6750","key":"10.1016\/j.peptides.2026.171517_bib7","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1038\/45809","article-title":"Human urotensin-II is a potent vasoconstrictor and agonist for the orphan receptor GPR14","volume":"401","author":"Ames","year":"1999","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.peptides.2026.171517_bib8","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.tips.2003.12.005","article-title":"From 'gills to pills': urotensin-II as a regulator of mammalian cardiorenal function","volume":"25","author":"Douglas","year":"2004","journal-title":"Trends Pharmacol. Sci."},{"issue":"9","key":"10.1016\/j.peptides.2026.171517_bib9","doi-asserted-by":"crossref","first-page":"924","DOI":"10.2174\/1389203718666170829162335","article-title":"Urotensin II: molecular mechanisms of biological activity","volume":"19","author":"Svistunov","year":"2018","journal-title":"Curr. Protein Pept. Sci."},{"key":"10.1016\/j.peptides.2026.171517_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.crphys.2024.100126","article-title":"Urotensin II system in chronic kidney disease","volume":"7","author":"Michael","year":"2024","journal-title":"Curr. Res. Physiol."},{"issue":"11","key":"10.1016\/j.peptides.2026.171517_bib11","doi-asserted-by":"crossref","first-page":"2170","DOI":"10.1016\/j.drudis.2019.08.005","article-title":"Novel insights into the role of urotensin II in cardiovascular disease","volume":"24","author":"Pereira-Castro","year":"2019","journal-title":"Drug. Discov. Today"},{"issue":"3","key":"10.1016\/j.peptides.2026.171517_bib12","doi-asserted-by":"crossref","first-page":"R107","DOI":"10.1530\/JOE-18-0505","article-title":"Urotensin II: an inflammatory cytokine","volume":"240","author":"Sun","year":"2019","journal-title":"J. Endocrinol."},{"issue":"5","key":"10.1016\/j.peptides.2026.171517_bib13","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1007\/s10620-009-0875-4","article-title":"Expression of urotensin II and its receptor in human liver cirrhosis and fulminant hepatic failure","volume":"55","author":"Leifeld","year":"2010","journal-title":"Dig. Dis. Sci."},{"issue":"6","key":"10.1016\/j.peptides.2026.171517_bib14","first-page":"845","article-title":"Increased expression of urotensin II and GPR14 in patients with cirrhosis and portal hypertension","volume":"25","author":"Liu","year":"2010","journal-title":"Int. J. Mol. Med."},{"issue":"6","key":"10.1016\/j.peptides.2026.171517_bib15","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1111\/hepr.12002","article-title":"H2S inhibits the activation of hepatic stellate cells and downregulates the expression of urotensin II","volume":"43","author":"Liu","year":"2013","journal-title":"Hepatol. Res."},{"issue":"6","key":"10.1016\/j.peptides.2026.171517_bib16","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0064895","article-title":"Inhibition of UII\/UTR system relieves acute inflammation of liver through preventing activation of NF-kappaB pathway in ALF mice","volume":"8","author":"Liang","year":"2013","journal-title":"PLoS. One"},{"issue":"6","key":"10.1016\/j.peptides.2026.171517_bib17","first-page":"953","article-title":"The urotension II antagonist SB-710411 arrests fibrosis in CCL4 cirrhotic rats","volume":"2","author":"Liu","year":"2009","journal-title":"Mol. Med. Rep."},{"issue":"3","key":"10.1016\/j.peptides.2026.171517_bib18","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0121383","article-title":"The UII\/UT system mediates upregulation of proinflammatory cytokines through p38 MAPK and NF-kappaB pathways in LPS-stimulated Kupffer cells","volume":"10","author":"Liu","year":"2015","journal-title":"PLoS. One"},{"issue":"4","key":"10.1016\/j.peptides.2026.171517_bib19","doi-asserted-by":"crossref","first-page":"284","DOI":"10.3892\/mmr.2021.11923","article-title":"Urantide decreases hepatic steatosis in rats with experimental atherosclerosis via the MAPK\/Erk\/JNK pathway","volume":"23","author":"Cui","year":"2021","journal-title":"Mol. Med. Rep."},{"issue":"3","key":"10.1016\/j.peptides.2026.171517_bib20","doi-asserted-by":"crossref","first-page":"308","DOI":"10.4062\/biomolther.2016.219","article-title":"A Novel Urotensin II Receptor Antagonist, KR-36996 Inhibits Smooth Muscle Proliferation through ERK\/ROS Pathway","volume":"25","author":"Kim","year":"2017","journal-title":"Biomol. Ther. (Seoul. )"},{"key":"10.1016\/j.peptides.2026.171517_bib21","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.ejphar.2017.02.003","article-title":"A novel urotensin II receptor antagonist, KR-36996, improved cardiac function and attenuated cardiac hypertrophy in experimental heart failure","volume":"799","author":"Oh","year":"2017","journal-title":"Eur. J. Pharmacol."},{"issue":"5","key":"10.1016\/j.peptides.2026.171517_bib22","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0127991","article-title":"Mouse models of diet-induced nonalcoholic steatohepatitis reproduce the heterogeneity of the human disease","volume":"10","author":"Machado","year":"2015","journal-title":"PLoS. One"},{"issue":"5","key":"10.1016\/j.peptides.2026.171517_bib23","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1194\/jlr.M800042-JLR200","article-title":"Mechanisms of hepatic steatosis in mice fed a lipogenic methionine choline-deficient diet","volume":"49","author":"Rinella","year":"2008","journal-title":"J. Lipid Res."},{"issue":"7","key":"10.1016\/j.peptides.2026.171517_bib24","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1161\/CIRCRESAHA.107.168799","article-title":"Urotensin II receptor knockout mice on an ApoE knockout background fed a high-fat diet exhibit an enhanced hyperlipidemic and atherosclerotic phenotype","volume":"105","author":"Bousette","year":"2009","journal-title":"Circ. Res."},{"issue":"1","key":"10.1016\/j.peptides.2026.171517_bib25","doi-asserted-by":"crossref","DOI":"10.1530\/JOE-22-0194","article-title":"Treating inflammation to combat non-alcoholic fatty liver disease","volume":"256","author":"Wiering","year":"2023","journal-title":"J. Endocrinol."},{"issue":"1","key":"10.1016\/j.peptides.2026.171517_bib26","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1152\/physrev.00013.2007","article-title":"Hepatic stellate cells: protean, multifunctional, and enigmatic cells of the liver","volume":"88","author":"Friedman","year":"2008","journal-title":"Physiol. Rev."},{"issue":"7","key":"10.1016\/j.peptides.2026.171517_bib27","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1038\/nrgastro.2017.38","article-title":"Mechanisms of hepatic stellate cell activation","volume":"14","author":"Tsuchida","year":"2017","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"issue":"1","key":"10.1016\/j.peptides.2026.171517_bib28","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1111\/j.1745-7254.2007.00485.x","article-title":"Urotensin II accelerates cardiac fibrosis and hypertrophy of rats induced by isoproterenol","volume":"28","author":"Zhang","year":"2007","journal-title":"Acta Pharmacol. Sin."},{"issue":"3","key":"10.1016\/j.peptides.2026.171517_bib29","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1007\/s10753-011-9421-6","article-title":"The efficiency of a urotensin II antagonist in an experimental lung fibrosis model","volume":"35","author":"Onat","year":"2012","journal-title":"Inflammation"},{"issue":"5","key":"10.1016\/j.peptides.2026.171517_bib30","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1016\/j.peptides.2007.08.020","article-title":"Increased circulating urotensin II in cirrhosis: potential implications in liver disease","volume":"29","author":"Kemp","year":"2008","journal-title":"Peptides"},{"issue":"4","key":"10.1016\/j.peptides.2026.171517_bib31","doi-asserted-by":"crossref","first-page":"688","DOI":"10.3892\/mmr.2021.12329","article-title":"Urantide prevents CCl4\u2011induced acute liver injury in rats by regulating the MAPK signalling pathway","volume":"24","author":"Li","year":"2021","journal-title":"Mol. Med. Rep."},{"issue":"12","key":"10.1016\/j.peptides.2026.171517_bib32","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1016\/j.tem.2017.10.007","article-title":"Mitogen-Activated Protein Kinase Regulation in Hepatic Metabolism","volume":"28","author":"Lawan","year":"2017","journal-title":"Trends Endocrinol. Metab."},{"issue":"3","key":"10.1016\/j.peptides.2026.171517_bib33","first-page":"172","article-title":"Function of Mitogen-Activated Protein Kinases in Hepatic Inflammation","volume":"2","author":"Westenberger","year":"2021","journal-title":"J. Cell. Signal."},{"key":"10.1016\/j.peptides.2026.171517_bib34","doi-asserted-by":"crossref","first-page":"17138","DOI":"10.1038\/s41598-021-96612-0","article-title":"Identification of new target proteins of a Urotensin-II receptor antagonist using transcriptome-based drug repositioning approach","volume":"11","author":"Lim","year":"2021","journal-title":"Sci. Rep."}],"container-title":["Peptides"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0196978126000549?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0196978126000549?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T20:40:17Z","timestamp":1790196017000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0196978126000549"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":34,"alternative-id":["S0196978126000549"],"URL":"https:\/\/doi.org\/10.1016\/j.peptides.2026.171517","relation":{},"ISSN":["0196-9781"],"issn-type":[{"value":"0196-9781","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"KR-36996, an orally active urotensin II receptor antagonist, attenuates hepatic inflammation and fibrosis in methionine- and choline-deficient diet-induced fibrosing steatohepatitis","name":"articletitle","label":"Article Title"},{"value":"Peptides","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.peptides.2026.171517","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"171517"}}